Treatment Approaches for Axonal vs Demyelinating Neuropathies

Demyelinating Neuropathies

The American College of Rheumatology recommends initiating pulse intravenous methylprednisolone combined with intravenous cyclophosphamide for inflammatory demyelinating conditions such as lupus-associated peripheral neuropathy or optic neuropathy 3
The European League Against Rheumatism suggests considering intravenous immunoglobulin (IVIG), plasma exchange, or rituximab for severe cases or those not responding to first-line therapy 3
Acute inflammatory demyelinating polyneuropathy (AIDP/Guillain-Barré) shows macrophage-mediated demyelination with lymphocytic infiltration and responds to urgent hospitalization with respiratory monitoring, according to the American Academy of Neurology 1
Waldenström's macroglobulinemia-associated demyelinating neuropathy (anti-MAG positive in 50% of cases) presents as slowly progressing, symmetrical sensory peripheral neuropathy affecting the feet initially, as stated by the European Society for Medical Oncology 4

The American Diabetes Association recommends optimizing glucose control in diabetic neuropathy to prevent or delay neuropathy development in type 1 diabetes and slow progression in type 2 diabetes, with a strength of evidence rated as high 2
The European Society for Medical Oncology suggests discontinuing or dose-reducing causative chemotherapy agents when drug-induced axonal neuropathy occurs (bortezomib, thalidomide), with a strength of evidence rated as moderate 5, 6, 7
For bortezomib-induced neuropathy (predominantly sensory, small-fiber axonal): implementing protocol-specified dose-modification guidelines, with median time to improvement of 47 days after dose reduction or discontinuation, as recommended by the European Society for Medical Oncology 6, 7
For thalidomide-induced neuropathy (length-dependent axonal affecting small and large fibers): 70% of patients develop neuropathy after 12 months of treatment, requiring dose reduction or discontinuation, according to the European Society for Medical Oncology 6, 7
The American Academy of Neurology states that no pharmacological agents are effective for preventing chemotherapy-induced peripheral neuropathy; pretreatment assessment and ongoing clinical evaluation before every cycle are critical, with a strength of evidence rated as high 5

The American Academy of Neurology recommends initiating pregabalin (300-600 mg/day), duloxetine (60 mg once daily), or gabapentin (300-2,400 mg/day) as first-line pharmacologic treatments for neuropathic pain in axonal neuropathies, with a strength of evidence rated as high 2

Axonal degeneration shows progressive reduction of sensory nerve action potential (SNAP) amplitude with relative preservation of nerve conduction velocity, as stated by the American Academy of Neurology 5, 2
Conduct electrodiagnostic studies to confirm diagnosis and determine the pattern, as this directly impacts treatment decisions, according to the American Academy of Neurology 1, 2
Standard nerve conduction studies may be completely normal in small fiber neuropathy (common with bortezomib), as noted by the European Society for Medical Oncology 5, 2
Skin biopsy with intraepidermal nerve fiber (IENF) density measurement is the gold standard for diagnosing small fiber neuropathy, with 45-90% sensitivity and 95-97% specificity, according to the American Academy of Neurology 1, 2

Do not rely solely on neurophysiology in small fiber neuropathy: conventional EMG and nerve conduction studies will be normal; skin biopsy is required, as stated by the European Society for Medical Oncology 5, 2
Monitor for autonomic neuropathy (orthostatic hypotension, bladder dysfunction) particularly with bortezomib, which occurs in approximately 10% of patients and can be difficult to recognize, according to the European Society for Medical Oncology 6